AstraZeneca Hopes Danicopan Interim Data Will Prove Sufficient For NDA Filing
Executive Summary
Danicopan seen as potential add-on therapy for paroxysmal nocturnal hemoglobinuria patients getting suboptimal results from Soliris or Ultomiris therapy. AstraZeneca will investigate filing for approval on 12-week data.
You may also be interested in...
Novartis Poised To Face Off With AstraZeneca In PNH After Second Iptacopan Trial
The Phase III APPOINT-PNH study, testing iptacopan in treatment-naïve PNH patients, met its primary endpoint, positioning the oral drug as a potential new competitor to Soliris and Ultomiris.
On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.
Apellis’ Empaveli Data In Frontline PNH Incremental, But Still Helpful
While the drug appears more efficacious than Alexion’s C5 inhibitors, those drugs could prove difficult to dethrone given how entrenched they are in PNH therapy.